Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Left Ventricular Systolic Dysfunction Clear all
Completed Phase 4 Interventional Results available

A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.

NCT03456856
View directory record Official record
Conditions
Heart Failure (HF)
Interventions
Ivabradine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Wilmington, Delaware • Detroit, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 19, 2026, 1:17 PM EDT
Not listed No phase listed Observational

CarDiac MagnEtic Resonance for Primary Prevention Implantable CardioVerter DebrillAtor ThErapy: an International Registry (DERIVATE)

NCT03352648
View directory record Official record
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Not listed
Lead sponsor
Gianluca Pontone, MD, PhD
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 19, 2026, 1:17 PM EDT
Completed No phase listed Observational

Patient and Physician Survey Determinants of Appropriate ICD Utilization

NCT01514773
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Not listed
Lead sponsor
Todd M Koelling, MD
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Diabetes on Left Ventricular Remodeling

NCT01052272
View directory record Official record
Conditions
Diabetes
Interventions
Ramipril, Candesartan cilexetil, Allopurinol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

NCT01807221
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo, Inspra (eplerenone)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 19, 2026, 1:17 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 18 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
22
States / cities
Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 1:17 PM EDT
Terminated Phase 3 Interventional

A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System

NCT01614652
View directory record Official record
Conditions
Congestive Heart Failure, Left Ventricular (LV) Systolic Dysfunction
Interventions
CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)
Device
Lead sponsor
CardioKinetix, Inc
Industry
Eligibility
18 Years to 79 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
67
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Phase 3 Interventional Results available

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

NCT02025621
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
Interventions
Levosimendan, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Burlington, Alabama • Huntsville, Alabama • Sacramento, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 19, 2026, 1:17 PM EDT
Recruiting No phase listed Observational

STICH3C Cardiac Magnetic Resonance Observational Study

NCT07133984
View directory record Official record
Conditions
Ischemic Left Ventricle Systolic Dysfunction, Multivessel Coronary Artery Disease
Interventions
Cardiac Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Brooklyn, New York • Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 1:17 PM EDT
Withdrawn No phase listed Observational

Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery

NCT04143997
View directory record Official record
Conditions
Peripartum Cardiomyopathy, Diastolic Dysfunction
Interventions
A clinical Transthoracic echocardiogram
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 19, 2026, 1:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Acute Cardiovascular Effects of Marathon Running Using Magnetic Resonance Imaging

NCT00752752
View directory record Official record
Conditions
Myocardial Ischemia, Left Ventricular Systolic Dysfunction, Elevated Cardiac Enzymes
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 19, 2026, 1:17 PM EDT
Not listed No phase listed Observational

SCD-HeFT 10 Year Follow-up

NCT01058837
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Congestive Heart Failure, Ischemic and Non-ischemic Cardiomyopathy, Sudden Cardiac Death Primary Prevention
Interventions
Not listed
Lead sponsor
Seattle Institute for Cardiac Research
Other
Eligibility
18 Years to 90 Years
Enrollment
1,855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 19, 2026, 1:17 PM EDT
Completed No phase listed Observational

The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort

NCT01340963
View directory record Official record
Conditions
Chagas Cardiomyopathy, Cardiac Arrhythmia, Stroke, Left Ventricular Function Systolic Dysfunction, Cardiac Death
Interventions
Not listed
Lead sponsor
Universidade Gama Filho
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Not applicable Interventional Results available

Heart Rate Response to Regadenoson and Sudden Cardiac Death

NCT01842035
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Sudden Cardiac Death
Interventions
regadenoson
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

NCT00414609
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Aliskiren, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Novartis US, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Not applicable Interventional Results available

REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)

NCT00271154
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
34
States / cities
Huntsville, Alabama • Anchorage, Alaska • Redwood City, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Phase 3 Interventional Results available

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

NCT00358215
View directory record Official record
Conditions
Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
2,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
254
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Phase 4 Interventional

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

NCT00082589
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
53
States / cities
Castro Valley, California • San Diego, California • Santa Rosa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Phase 2 Interventional Results available

Cardiac Safety Study in Patients With HER2 + Breast Cancer

NCT01904903
View directory record Official record
Conditions
HER2 Positive Breast Cancer, Left Ventricular Function Systolic Dysfunction
Interventions
Trastuzumab, Pertuzumab, Ado Trastuzumab Emtansine
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

NCT03785405
View directory record Official record
Conditions
Heart Failure
Interventions
sacubitril/valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
15
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

NCT02032004
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Rexlemestrocel-L, Sham Comparator
Biological · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
56
States / cities
Birmingham, Alabama • Gilbert, Arizona • Mesa, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 19, 2026, 1:17 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

NCT00748579
View directory record Official record
Conditions
Heart Failure
Interventions
CK-1827452
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 19, 2026, 1:17 PM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

NCT00684060
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 19, 2026, 1:17 PM EDT
Terminated Phase 2 Interventional Results available

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

NCT01065051
View directory record Official record
Conditions
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 19, 2026, 1:17 PM EDT